

## POSTER PRESENTATION

## Open Access

# Level of PD-1 expression on CD8<sup>+</sup> T cells influence prognosis and respond to PD-1 therapy in a murine model

Benjamin A Kansy<sup>1\*</sup>, Raghvendra M Srivastava<sup>2</sup>, Hyun-Bae Jie<sup>2</sup>, Gulidanna Shayan<sup>2</sup>, Yu Lei<sup>2</sup>, Jing Li<sup>2</sup>, William Gooding<sup>3</sup>, Sven Brandau<sup>4</sup>, Stephan Lang<sup>4</sup>, Nicole Schmitt<sup>5</sup>, Gordon J Freeman<sup>6</sup>, David A Clump<sup>7</sup>, Robert L Ferris<sup>2</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

## Introduction

Prognosis varies dramatically in head and neck squamous cell carcinoma (HNSCC) based on HPV status. In HPV<sup>+</sup> patients, programmed death (PD)-1 expression has been linked to a better clinical outcome. We hypothesized that extent of PD-1 expression may differentially impact T cell phenotype, patient prognosis and response to anti-PD-1 immunotherapy in a murine HPV<sup>+</sup> cancer model.

## Material and methods

Freshly isolated tumor infiltrating lymphocytes (TIL) from HNSCC patients were stained by flow cytometry for expression level of PD-1 expression (PD-1<sup>high</sup> vs. PD-1<sup>low</sup>), granzyme B, or IFN- $\gamma$  secretion by ELISPOT. The prognostic impact of PD-1<sup>high</sup> vs. PD-1<sup>low</sup> T cells was determined in a cohort of HNSCC patients (n=56, median follow up=19 mo). In a murine HNSCC model, PD-1<sup>high</sup> and PD-1<sup>low</sup> fractions were compared from CD3<sup>+</sup> CD8<sup>+</sup> PD-1<sup>+</sup> cells and analyzed according to different treatment groups (untreated, anti-PD-1 mAb, radiotherapy and 3 different anti-PD-1/radiotherapy combinations).

## Results

CTLA-4 and PD-1 were significantly upregulated on both HPV<sup>+</sup> and HPV<sup>-</sup> HNSCC patients' TIL, whereas PD-1<sup>+</sup> CD8<sup>+</sup> cells were significantly enriched in TIL from HPV<sup>+</sup> patients (p=0.006). Interestingly, PD-1<sup>high</sup> cells represented a more dysfunctional phenotype, with severely

compromised IFN- $\gamma$  secretion (phigh CD8<sup>+</sup> TIL were more likely to be HPV<sup>-</sup> and had a worse disease free survival (HR = 2.25; 95% CI = 1.46 – 3.15; p < .0001), while high fractions of PD-1<sup>low</sup> T cells were associated with better clinical outcome (HR= 0.19, 95% CI = .07 - .49, p = .0006), and were seen preferentially in HPV<sup>+</sup> HNSCC patients. In the murine HNSCC model, anti-PD-1 mAb plus radiotherapy resulted in optimal tumor elimination, which was associated with an elimination of PD-1<sup>high</sup> CD8<sup>+</sup> T cells and – most importantly – increase in PD-1<sup>low/intermed</sup> T cell frequencies (p < 0.5).

## Discussion

Consideration of different PD-1 expression levels on TIL segregates PD-1 expression as a marker of activated, competent tumor reactive T cells on the one hand (low/intermed expression), and as a marker of exhausted, dysfunctional cells in the tumor microenvironment on the other hand (high expression). These results emphasize the crucial role of differential PD-1 expression levels on HNSCC patients' effector T cells for prognosis and as a potential novel biomarker for anti-PD-1/PD-L1 based immunotherapy.

## Authors' details

<sup>1</sup>Department of Otorhinolaryngology, University Hospital Essen, Germany; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. <sup>2</sup>University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. <sup>3</sup>Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA, Pittsburgh, PA, USA. <sup>4</sup>Department of Otorhinolaryngology, University Hospital Essen, Germany, Essen, Germany. <sup>5</sup>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, USA. <sup>6</sup>Dana-Farber/Harvard Cancer Center,

<sup>1</sup>Department of Otorhinolaryngology, University Hospital Essen, Germany; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA  
Full list of author information is available at the end of the article

Boston, MA, USA. <sup>7</sup>Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P228

**Cite this article as:** Kansy *et al.*: Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model. *Journal for ImmunoTherapy of Cancer* 2015 3(Suppl 2):P228.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

